Atlas Venture
Atlas Venture is a Cambridge-based early-stage venture capital firm that creates and builds biotechnology companies through a seed-led incubator model, partnering with entrepreneurs-in-residence to spin out therapeutics startups across autoimmune, oncology, metabolic, and rare disease indications for institutional limited partners.
- Company typePrivate
- Founded1980
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Atlas Venture does
Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that creates and builds early-stage biotechnology companies. Founded originally in the 1980s and repositioned around life sciences in the early 1990s, the firm operates a company-creation model in which partners and Entrepreneurs-in-Residence identify transformative scientific innovation, spin out new entities, and serve as long-term operating partners from formation through commercialization. Over more than 30 years the firm has launched 92 startups from its incubator, with portfolio companies producing 25+ medicines, 43 IPOs, and 39 M&A exits.
The firm manages multiple venture funds, with the most recent disclosed vehicles being the $300 million Second Opportunity Fund (October 2021), the $450 million Fund XIII (March 2022), and the $400 million Third Opportunity Fund (September 2025), alongside legacy Funds VI through XIV and AVOF I through III. Atlas's core products are (1) venture capital investment services across seed through growth stages, (2) company creation and incubation through the EIR program, and (3) the Nautilus leadership community, Compass startup playbook, and Investor Reporting Portal platforms that provide portfolio operations support. The investment team includes six active partners (David Grayzel, Bruce Booth, Jean-François Formela, Jason Rhodes, Kevin Bitterman, and Michael Gladstone), three principals, four senior associates, and an extensive bench of venture partners, EIRs, and Atlas Advisors composed of former pharma R&D leaders and biotech CEOs.
Atlas Venture earns revenue through standard venture capital mechanics: management fees on committed fund capital and carried interest on realized exits from portfolio company IPOs (such as Kailera Therapeutics' $625 million Nasdaq offering in April 2026) and M&A transactions. Customers are two-sided: institutional limited partners supplying fund capital, and life-science entrepreneurs and scientists receiving company-formation capital, operating support, and ecosystem access. Geographic focus is the U.S. Northeast with select international portfolio exposure (e.g., Italy-based AAVantgarde Bio).
Atlas Venture firmographics
Firmographics- Name
- Atlas Venture
- Legal name
- Atlas Venture
- Website
- http://atlasventure.com
- Company type
- Private
- Founded year
- 1980
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Atlas Venture is a Cambridge-based early-stage venture capital firm that creates and builds biotechnology companies through a seed-led incubator model, partnering with entrepreneurs-in-residence to spin out therapeutics startups across autoimmune, oncology, metabolic, and rare disease indications for institutional limited partners.
- Ownership category
- akta.pro rank
Atlas Venture industry classification
Industry- Product category
- Life Sciences Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), All Other Financial Investment Activities (52399), Miscellaneous Financial Investment Activities (523999)
- SIC
- Investment Advice (6282), Investors, Nec (6799)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
- akta.pro secondary industry
- M&A Advisory (Buy-side/Sell-side) (BPAHADAC)
Keywords
Where Atlas Venture is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Atlas Venture business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Fund Management: Atlas Venture manages multiple venture funds (X, XI, XII, XIII, XIV, AVOF I, II, III, and legacy funds VI, VII, VIII, IX) and generates revenue through management fees and carried interest from portfolio company exits.
- Portfolio Company Equity: Returns generated through equity stakes in portfolio companies, including IPOs and M&A exits such as 43 IPOs and 39 M&A exits historically.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Atlas Venture product offering
Product offeringCore offering
Atlas Venture is a life sciences venture capital firm that creates, incubates, and invests in early-stage biotechnology companies through multiple dedicated funds. The firm partners shoulder-to-shoulder with Entrepreneurs-In-Residence and operators to build platform and product companies, providing capital, strategic guidance, and operational resources from seed through commercialization, and generating returns via management fees, carried interest, and equity stakes in portfolio exits.
Product overview
Atlas Venture is a venture capital firm that builds breakthrough biotechnology companies through a seed-led investment model. The firm operates as a company creation platform, partnering with entrepreneurs-in-residence to identify transformative science and build new ventures. Atlas provides funding vehicles (multiple fund generations including Funds X through XIV, AVOF I, II, III, and Opportunity Funds), strategic resources through its Nautilus community platform for portfolio leadership, and Compass as a company-building playbook. The firm has launched 92 startups, achieved 43 IPOs, and 39 M&A exits, with over 25 medicines made by portfolio companies.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- 25+ medicines developed by portfolio companies
- +3 more outcomes
Companies that use Atlas Venture
Customer profileSegments2 records
Ideal customer profiles2 records
Atlas Venture technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Atlas Venture partnerships and signals
Strategic signalScale indicators8 records
Recent moves8 records
Expansion highlights6 records
Atlas Venture competitors and assessment
Company assessmentDirect peers
- Flagship Pioneering: Flagship Pioneering is a direct peer - a Cambridge-based biotech company creation platform that builds breakthrough life sciences ventures from inception using an "origination" model closely analogous to Atlas's incubator approach. Both firms operate scientist-EIR partnerships to launch new biotech companies rather than purely funding external teams.
- Third Rock Ventures: Third Rock Ventures is a direct peer - a Boston-based venture firm that builds biotech companies from inception by partnering with entrepreneurs and scientists, mirroring Atlas's seed-led company creation model. Both firms focus on launching and operating new biotech ventures rather than just providing capital.
- ARCH Venture Partners: ARCH Venture Partners is a direct peer - one of the largest early-stage biotech VCs that co-invests alongside Atlas in deals like Kailera Therapeutics and nChroma Bio, with a comparable focus on creating companies from breakthrough university and biotech research.
- Versant Ventures: Versant Ventures is a direct peer - a healthcare-focused VC that builds biotech companies through in-house incubation (e.g., Inception Sciences) similar to Atlas's EIR-driven model, investing across multiple fund vintages with comparable life sciences focus.
- 5AM Ventures: 5AM Ventures is a direct peer - an early-stage life sciences VC firm with a hands-on company creation approach that has operated comparable fund vintages and portfolio strategies to Atlas, often co-investing in seed and Series A biotech rounds.
- OrbiMed: OrbiMed is a direct peer - one of the largest healthcare-dedicated investment firms globally, participating in many of the same rounds as Atlas (Q32 Bio, etc.) with a broader life sciences mandate spanning venture, growth, and public equities.
- RA Capital Management: RA Capital Management is a direct peer - a healthcare-focused crossover fund that co-leads many of Atlas's portfolio financings (Kinaset, TRIANA, Q32 Bio), offering a complementary late-stage and public-equity capability that overlaps with Atlas's biotech investing universe.
- Foresite Capital: Foresite Capital is a direct peer - a healthcare and biotech-focused investment firm that has co-invested with Atlas and operates comparable fund vintages targeting therapeutic and biomedical innovation, often overlapping in syndicate participation.
- Apple Tree Partners: Apple Tree Partners is a direct peer - a biotech-focused venture firm that builds companies through internal incubation, comparable to Atlas's model, and competes for similar life sciences talent and deal flow in the Northeast US ecosystem.
Broad incumbents
- New Enterprise Associates (NEA): NEA is a broad incumbent - a large multi-stage venture firm with a significant healthcare and biotech practice that competes for similar deals and LPs, though its broader tech focus makes it less specialized than Atlas in biotech venture creation.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Atlas Venture social profiles
Digital presenceAtlas Venture financial estimates
Financial estimateRevenue estimate
Valuation estimate
Atlas Venture leadership team
Management profileNumber of profiles
Profiles23 records
Atlas Venture funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Atlas Venture M&A and investment
M&A and investmentM&A
Investments680 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Atlas Venture
What does Atlas Venture do?
Atlas Venture is a life sciences venture capital firm that creates, incubates, and invests in early-stage biotechnology companies through multiple dedicated funds. The firm partners shoulder-to-shoulder with Entrepreneurs-In-Residence and operators to build platform and product companies, providing capital, strategic guidance, and operational resources from seed through commercialization, and generating returns via management fees, carried interest, and equity stakes in portfolio exits.
Is Atlas Venture a public or private company?
Atlas Venture is a private company. It is classified as management employee owned and is currently operating.
When was Atlas Venture founded?
Atlas Venture was founded in 1980. It employs 11 to 50 people.
Where is Atlas Venture based?
Atlas Venture is headquartered in Cambridge, United States, in the North America region.
How does Atlas Venture make money?
Two revenue lines are on record. Fund Management is the primary driver. The others are portfolio Company Equity.
Who are Atlas Venture's main competitors?
Direct peers on record are Flagship Pioneering, Third Rock Ventures, ARCH Venture Partners, Versant Ventures, 5AM Ventures, OrbiMed, RA Capital Management, Foresite Capital and Apple Tree Partners. New Enterprise Associates (NEA) is listed as a broad incumbent.
Does Atlas Venture have an API?
No public API is recorded for Atlas Venture.
What industry is Atlas Venture in?
Atlas Venture's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of BPAHADAC, M&A Advisory (Buy-side/Sell-side). Its NAICS code is 523940 and its SIC code is 6282.